Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
Matthew A InghamJacob B AllredLi ChenBiswasjit DasBose S KochupurakkalKatherine GanoSuzanne GeorgeSteven AttiaMelissa A BurgessMahesh SeetharamSosipatros A BoikosNam Q BuiJames L ChenJulia L CloseGregory M CotePremal H ThakerSusan Percy IvySminu BoseAlan D' AndreaAdrian Mariño-EnriquezGeoffrey I ShapiroGary K SchwartzPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Olaparib and temozolomide met the prespecified primary end point and provided meaningful clinical benefit in patients with advanced, pretreated uLMS.